← Eichor
Condition: Reversal Of Neuromuscular Blockade Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Reversal Of Neuromuscular Blockade

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Single Ascending Dose of HRS-2162 in Healthy Subjects
Phase 1 · 1 location(s) · Fujian Shengdi Pharmaceutical Co., Ltd. · NCT07195604Pharmacological Reversal of Neuromuscular Blockade in Critically Ill Patients
NA · 1 location(s) · Seoul National University Hospital · NCT05993390Recovery Times of Half Dose Sugammadex and Neostigmine for Rocuronium-induced Neuromuscular Blockade
Phase 1/Phase 2 · 1 location(s) · Universitas Padjadjaran · NCT06794450The Effect of Neostigmine and Sugammadex on the Optic Nerve Sheath Diameter
Phase 4 · 1 location(s) · Cukurova University · NCT07666984Neuromuscular Blockade Comparison for GI-2 Recovery After Bowel Resection
Phase 4 · 1 location(s) · University of California, Irvine · NCT06112353Sugammadex-Induced Clenching During Neuromuscular Blockade Reversal
NA · 1 location(s) · Wonkwang University Hospital · NCT06962007
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.